NASDAQ:SYBX Synlogic (SYBX) Stock Price, News & Analysis $0.68 -0.02 (-3.19%) As of 01:41 PM Eastern Add Compare Share Share Stock Analysis Stock AnalysisAnalyst ForecastsChartCompetitorsEarningsInsider TradesOwnershipSEC FilingsTrendsBuy This Stock About Synlogic Stock (NASDAQ:SYBX) View Price History Chart DataSkip Price History Chart 1 Day 5 Days 30 Days 90 Days 1 Year Advanced 1 Day 1 Day 5 Days 30 Days 90 Days 1 Year Advanced Show volume Show extended hours Get Synlogic alerts:Sign Up Key Stats Today's Range$0.61▼$0.7050-Day Range$0.60▼$0.7952-Week Range$0.54▼$1.96Volume1,065 shsAverage Volume58,325 shsMarket Capitalization$7.92 millionP/E RatioN/ADividend YieldN/APrice TargetN/AConsensus RatingSell Company Overview Synlogic, Inc., a clinical-stage biopharmaceutical company, engages in the discovery and development of synthetic biotics to treat metabolic diseases in the United States. Its pipeline include SYNB1618, an orally administered, non-systemically absorbed drug candidate to treat phenylketonuria; SYNB1934, an orally administered, non-systemically absorbed drug candidate, which is in Phase III clinical trial to treat phenylketonuria; SYNB1353, an orally administered, non-systemically absorbed drug candidate, which is in Phase I clinical to treat homocystinuria; SYNB8802, an orally administered, non-systemically absorbed drug candidate that is in Phase II clinical trial for the treatment of enteric hyperoxaluria; and SYNB2081 to lower uric acid for the potential treatment of gout. The company has a collaboration agreement with F. Hoffmann-La Roche Ltd and Hoffmann-La Roche Inc. for the research and pre-clinical development of a synthetic biotic medicine for the treatment of inflammatory bowel disease; and Ginkgo Bioworks, Inc. Synlogic, Inc. is based in Cambridge, Massachusetts. Read More Receive SYBX Stock News and Ratings via Email Sign-up to receive the latest news and ratings for Synlogic and its competitors with MarketBeat's FREE daily newsletter. Submit View SMS TermsSMS is currently available in Australia, Belgium, Canada, France, Germany, Ireland, Italy, New Zealand, the Netherlands, Singapore, South Africa, Spain, Switzerland, the United Kingdom, and the United States. By entering your phone number and clicking the sign-up button, you agree to receive periodic text messages from MarketBeat at the phone number you submitted, including texts that may be sent using an automatic telephone dialing system. Message and data rates may apply. Message frequency will vary. Messages will consist of stock alerts, news stories, and partner advertisements/offers. Consent is not a condition of the purchase of any goods or services. Text HELP for help/customer support. Unsubscribe at any time by replying "STOP" to any text message that you receive from MarketBeat or by visiting our mailing preferences page. Read our full terms of service and privacy policy. SYBX Stock News HeadlinesSynlogic (NASDAQ:SYBX) Stock Passes Below Fifty Day Moving Average - Time to Sell?June 17, 2026 | americanbankingnews.comSynlogic Challenges Nasdaq Delisting NoticeNovember 26, 2025 | tipranks.comMarket Legend DUMPS 537,742 Nvidia Shares...One of the most influential tech investors of all time just sold 537,742 shares of Nvidia - along with his entire stakes in Apple, Microsoft, and Tesla. Analyst Luke Lango, once ranked the world's top stock-picker among 15,000 analysts, says it is not just about what was sold. He and a 26-year Wall Street veteran have identified the asset class this billionaire - plus Jeff Bezos, Elon Musk, and Sam Altman - are buying next, with up to $700 billion expected to flow in this year alone. One company in their 'Billionaire's Backdoor Portfolio' trades near $50 a share and may be the single most essential technology keeping the U.S. AI expansion running.June 24 at 1:00 AM | InvestorPlace (Ad)We Think Synlogic (NASDAQ:SYBX) Can Afford To Drive Business GrowthSeptember 18, 2025 | uk.finance.yahoo.comSynlogic, Inc. (SYBX) Latest Stock News & Headlines - Yahoo FinanceJune 28, 2025 | finance.yahoo.comSynlogic's executive sells shares worth $2,802February 5, 2025 | msn.comSynlogic Reports Q3 2024 Financial OutcomesNovember 14, 2024 | markets.businessinsider.comSynlogic, Inc.: Synlogic Reports Third Quarter 2024 Financial ResultsNovember 13, 2024 | finanznachrichten.deSee More Headlines SYBX Stock Analysis - Frequently Asked Questions How have SYBX shares performed this year? Synlogic's stock was trading at $1.12 on January 1st, 2026. Since then, SYBX shares have decreased by 37.5% and is now trading at $0.6999. How were Synlogic's earnings last quarter? Synlogic, Inc. (NASDAQ:SYBX) released its quarterly earnings results on Thursday, November, 13th. The biotechnology company reported ($0.19) EPS for the quarter, missing analysts' consensus estimates of ($0.11) by $0.08. When did Synlogic's stock split? Synlogic shares reverse split before market open on Thursday, September 28th 2023.The 1-15 reverse split was announced on Thursday, September 28th 2023. The number of shares owned by shareholders was adjusted after the market closes on Thursday, September 28th 2023. An investor that had 100 shares of stock prior to the reverse split would have 7 shares after the split. When did Synlogic IPO? Synlogic (SYBX) raised $88 million in an initial public offering (IPO) on Wednesday, September 30th 2015. The company issued 6,250,000 shares at a price of $13.00-$15.00 per share. How do I buy shares of Synlogic? Shares of SYBX stock can be purchased through any online brokerage account. Popular online brokerages with access to the U.S. stock market include Charles Schwab, E*TRADE, Fidelity, and Vanguard Brokerage Services. What other stocks do shareholders of Synlogic own? Based on aggregate information from My MarketBeat watchlists, some other companies that Synlogic investors own include Sangamo Therapeutics (SGMO), Precision Drilling (PDS), First Financial Bankshares (FFIN), Sorrento Therapeutics (SRNE) and Exelixis (EXEL). Company Calendar Last Earnings11/13/2025Today6/24/2026Fiscal Year End12/31/2026Get Stock Alerts Health Indicator TradeSmith's Health IndicatorA long-term volatility-based measure designed for securities held 12 months or longer.Green: Strong and healthy uptrend with normal pullbacks.Yellow: Significant pullback but still within expected volatility.Red: Dropped beyond expected volatility; considered unhealthy. Yellow Zone (5m+) 1-Year History Jun 25 Sep 25 Dec 25 Mar 26 Jun 26 SYBX's financial health is in the Yellow zone, according to TradeSmith. SYBX has been in this zone for over 5 months. Industry, Sector and Symbol Stock ExchangeNASDAQ SectorMedical Industry MED - BIOMED/GENE Sub-IndustryPharmaceutical Products Current SymbolNASDAQ:SYBX CIK1527599 Webwww.synlogictx.com Phone(617) 401-9975Fax512-681-5201Employees80Year Founded2013Profitability EPS (Trailing Twelve Months)($0.06) Trailing P/E RatioN/A Forward P/E RatioN/A P/E GrowthN/ANet Income-$23.36 million Net MarginsN/A Pretax MarginN/A Return on Equity-26.47% Return on Assets-18.00% Debt Debt-to-Equity RatioN/A Current Ratio2.65 Quick Ratio2.65 Sales & Book Value Annual Sales$8 thousand Price / Sales990.59 Cash FlowN/A Price / Cash FlowN/A Book Value$1.09 per share Price / Book0.62Miscellaneous Outstanding Shares11,697,000Free Float11,392,000Market Cap$7.92 million OptionableNo Data Beta0.56 Social Links 7 Stocks That Could Be Bigger Than Tesla, Nvidia, and GoogleLooking for the next FAANG stock before everyone has heard about it? Click the link to see which stocks MarketBeat analysts think might become the next trillion dollar tech company.Get This Free Report This page (NASDAQ:SYBX) was last updated on 6/24/2026 by MarketBeat.com Staff. From Our PartnersQuick favor to ask youBill Poulos is giving away his 'Safe Trade Options Formula' book at no charge - the same book that sells for $...Profits Run | SponsoredMy feud with Zohran MamdaniNearly 40% of Americans now hold a positive view of socialism - and former hedge fund manager Whitney Tilson s...Stansberry Research | SponsoredPH: Do THESE 4 things to your bank account now …In a few short months, the US government could gain unprecedented powers over personal bank accounts - includi...Weiss Ratings | SponsoredVWAV: An Under-the-Radar Defense PlayVisionWave Holdings (NASDAQ: VWAV) is developing a multi-domain defense platform combining AI-powered analytic...Equiscreen | SponsoredThe Treasury just bought its own debtOn April 16th, the U.S. Treasury executed a $15 billion buyback of its own debt - the largest in history - whi...Golden Portfolio | SponsoredMarket Legend DUMPS 537,742 Nvidia Shares...One of the most influential tech investors of all time just sold 537,742 shares of Nvidia - along with his ent...InvestorPlace | SponsoredBuy this stock todayMarc Chaikin, founder of Chaikin Analytics, is sharing a strategy he calls 'Sell This, Buy That' - a way to mo...Chaikin Analytics | SponsoredElon Is Quietly Doubling Down on This Bizarre AssetYahoo Finance reports this technology 'May Unlock $400 Trillion' - and Bloomberg calls it 'unavoidable.' Elon ...Brownstone Research | Sponsored Adding Choose a watchlist: Watchlist Adding You have already added ten stocks to your watchlist. Upgrade to MarketBeat All Access to add more stocks to your watchlist. Adding Synlogic, Inc. Please log in to your account or sign up in order to add this asset to your watchlist. Share Synlogic With A Colleague Link copied to clipboard. Get 30 Days of MarketBeat All Access for Free Sign up for MarketBeat All Access to gain access to MarketBeat's full suite of research tools. Start Your 30-Day Trial MarketBeat All Access Features Best-in-Class Portfolio Monitoring Get personalized stock ideas. Compare portfolio to indices. Check stock news, ratings, SEC filings, and more. Stock Ideas and Recommendations See daily stock ideas from top analysts. Receive short-term trading ideas from MarketBeat. Identify trending stocks on social media. Advanced Stock Screeners and Research Tools Use our seven stock screeners to find suitable stocks. Stay informed with MarketBeat's real-time news. Export data to Excel for personal analysis. Sign in to your free account to enjoy these benefits In-depth profiles and analysis for 20,000 public companies. Real-time analyst ratings, insider transactions, earnings data, and more. Our daily ratings and market update email newsletter. Sign in to your free account to enjoy all that MarketBeat has to offer. Sign In Create Account Your Email Address: Email Address Required Your Password: Password Required Log In Email Me a Login Link or Sign in with Facebook Sign in with Google Forgot your password? Your Email Address: Please enter your email address. Please enter a valid email address Choose a Password: Please enter your password. Your password must be at least 8 characters long and contain at least 1 number, 1 letter, and 1 special character. Create My Account (Free) or Sign in with Facebook Sign in with Google By creating a free account, you agree to our terms of service. This site is protected by reCAPTCHA and the Google Privacy Policy and Terms of Service apply.
